BenevolentAI, a London-based clinical-stage AI-powered drug discovery company, announced on Monday that it has started trading on Euronext Amsterdam under the ticker symbol BAI.
The announcement comes after agreeing to go public through a merger with blank-check company Odyssey Acquisition at a valuation of €1.5B.
Through the business combination, BenevolentAI has received gross proceeds of €225M. The proceeds will enable BenevolentAI to accelerate the development of its clinical pipeline and continue investing in its technology platform.
As a part of the deal, Olivier Brandicourt, the former CEO of Sanofi, and Jean Raby, the former CEO of Natixis Investment Managers, have joined the board of BenevolentAI.